The FDA approval of Alkermes' new antipsychotic drug Lybalvi couldn't have gone any better for the company, but it could still face a big challenge positioning the new drug in the highly ...

The FDA approval of Alkermes' new antipsychotic drug Lybalvi couldn't have gone any better for the company, but it could still face a big challenge positioning the new drug in the highly ...

Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia) and Lybalvi (schizophrenia and bipolar ...